About this trial
This study aims to compare mid-to long-term outcomes of paclitaxel-coated balloon angioplasty with adjunctive debulking versus paclitaxel-coated balloon angioplasty alone for the treatment of chronic femoropopliteal artery diseases.
Eligibility criteria
Qualifiers
Subject age 18-85yrs.
Subject has been informed of the nature of the study, agrees to participate, and has signed a Medical Ethics Committee approved consent form.
Subject understands the duration of the study, agrees to attend follow-up visits, and agrees to complete the required testing.
Rutherford category 2-5.
Disqualifiers
Subject presents with acute arterial embolism or thrombosis requiring thrombectomy or thrombolysis for limb ischemia.
Subject has arterial occlusion caused by thromboangiitis obliterans (Buerger's disease) or other forms of immune-mediated vasculitis.
Subject has undergone surgery on the target vessel within the past 3 months, or has experienced repeated failures of endovascular therapy and is deemed unsuitable for further endovascular intervention.
Subject has an uncontrolled thrombophilia or hypercoagulable state.
Trial design
Treatments tested in this trial
- paclitaxel-coated balloon angioplasty
- paclitaxel-coated balloon angioplasty with debulking procedures